Achilles Therapeutics (ACHL)
(Delayed Data from NSDQ)
$1.00 USD
+0.01 (1.01%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $1.00 0.00 (0.00%) 5:14 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.00 USD
+0.01 (1.01%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $1.00 0.00 (0.00%) 5:14 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Zacks News
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Waters (WAT) Boosts Mass Spectrometry Clientele With Latest Move
by Zacks Equity Research
Waters (WAT) partners with the University of San Agustin to provide the latter with technology equipment in its newly developed mass spectrometry imaging center in the Philippines.
Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?
by Zacks Equity Research
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year.
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development
by Zacks Equity Research
Waters (WAT) launches new bioprocess walk-up solutions, automating sample prep and analysis from any bioreactor.
Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Jazz (JAZZ) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports better-than-expected second-quarter results as earnings and sales beat expectations. The company raises its financial guidance for 2023.
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year.
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock
by Zacks Equity Research
Achilles Therapeutics PLC Sponsored ADR (ACHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe
by Zacks Equity Research
Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise. Stiff competition remains an overhang.
Alnylam (ALNY) Gets FDA Approval for Oxlumo Label Expansion
by Zacks Equity Research
The FDA approves Alnylam's (ALNY) Oxlumo for treating primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients.
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy
by Zacks Equity Research
Allogene (ALLO) starts the pivotal phase II ALPHA2 study evaluating its allogeneic CAR T therapy, ALLO-501A in patients with relapsed/refractory large B-cell lymphoma.
Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why
by Zacks Equity Research
Apellis' (APLS) marketed drug, Empaveli, approved for treating paroxysmal nocturnal hemoglobinuria is driving revenues. The drug's label expansion studies also hold promise.
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
by Zacks Equity Research
IVERIC bio (ISEE) reports positive top-line data from the phase III GATHER2 study, evaluating its investigational candidate, Zimura, for the treatment of geographic atrophy. Stock up.
Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication
by Zacks Equity Research
The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104
by Zacks Equity Research
Immuneering (IMRX) files an investigational new drug (IND) application to the FDA to start a phase I/IIa study on IMM-1-104 for the treatment of advanced RAS mutant solid tumors. Stock up.
Sanofi (SNY) Gets FDA Nod for Rare Disease Drug Xenpozyme
by Zacks Equity Research
The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
by Zacks Equity Research
The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.
Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study
by Zacks Equity Research
Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Concern
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.
Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why
by Zacks Equity Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.